（文章来源：证券日报） 证券日报网讯艾德生物9月24日在互动平台回答投资者提问时表示，公司将持续加强与资本市场的沟 通。 ...

Core Viewpoint - The stock of Aide Biological has shown a slight increase of 1.56% year-to-date, with recent fluctuations indicating a decline over the past five and twenty trading days, while experiencing a rise over the last sixty days [2] Group 1: Stock Performance - On September 24, Aide Biological's stock rose by 2.01%, reaching a price of 22.85 CNY per share, with a trading volume of 84.03 million CNY and a turnover rate of 0.95%, resulting in a total market capitalization of 8.947 billion CNY [1] - Year-to-date, the stock has increased by 1.56%, with a decline of 2.18% over the last five trading days and 5.15% over the last twenty days, while showing a 7.38% increase over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Aide Biological reported a revenue of 579 million CNY, reflecting a year-on-year growth of 6.69%, and a net profit attributable to shareholders of 189 million CNY, which is a 31.41% increase compared to the previous year [2] - The company has distributed a total of 421 million CNY in dividends since its A-share listing, with 232 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, Aide Biological had 25,300 shareholders, an increase of 5.41% from the previous period, with an average of 15,393 circulating shares per shareholder, a decrease of 5.13% [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 31.67 million shares, a decrease of 3.52 million shares from the previous period, while Huabao Zhongzheng Medical ETF is a new fifth-largest shareholder with 9.04 million shares [3]

Core Viewpoint - The company has several products based on its proprietary technology that are currently in the registration application stage, indicating ongoing innovation and potential future revenue streams [2]. Group 1: Product Development - The company is developing multiple products based on its own intellectual property, which are in the registration application phase [2]. - Among these products is the HRD gene testing kit, which has been included in the special approval channel for innovative medical devices [2]. - Other products under development include gene mutation detection kits for c-Met, BRAF/TERT/RET/NTRK3 [2].

Core Viewpoint - The company has not conducted asset evaluations for its more than 30 approved medical device registration certificates [1] Group 1 - The company received approval for over 30 medical device registration certificates [1] - Investors inquired about the asset evaluation of these registration certificates on an investor interaction platform [1] - The company confirmed that no asset evaluations have been performed for the registered certificates [1]

Core Viewpoint - The stock of Aide Biological experienced a decline of 2.03% on September 12, with a current price of 23.66 CNY per share and a total market capitalization of 9.264 billion CNY, indicating a mixed performance in recent trading sessions [1]. Financial Performance - For the first half of 2025, Aide Biological reported a revenue of 579 million CNY, representing a year-on-year growth of 6.69%, and a net profit attributable to shareholders of 189 million CNY, which is a 31.41% increase compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 421 million CNY, with 232 million CNY distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 5.41% to 25,300, while the average circulating shares per person decreased by 5.13% to 15,393 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 31.6706 million shares, a decrease of 3.5159 million shares from the previous period [3]. - New entrants among the top ten circulating shareholders include Hua Bao Zhong Zheng Medical ETF, holding 9.0366 million shares [3]. Stock Performance - Year-to-date, Aide Biological's stock price has increased by 5.16%, but it has seen a decline of 4.56% over the last five trading days and a slight decrease of 1.05% over the past 20 days [1]. - The stock has shown a more favorable performance over the last 60 days, with an increase of 13.15% [1]. Business Overview - Aide Biological, established on February 21, 2008, and listed on August 2, 2017, specializes in the research, production, and sales of molecular diagnostic products for precision oncology, along with related testing services [1]. - The company's revenue composition includes 83.43% from testing reagents, 9.84% from clinical research services, 5.61% from testing services, and 1.12% from other sources [1].

Group 1 - The core point of the article is that Xiamen Aide Biological Medicine Technology Co., Ltd. has won the bid for the procurement project of electronic gastrointestinal endoscopy systems and high-throughput sequencing analysis platforms at Longyan First Hospital, with a bid amount of 851,000 [1][2] - The procurement project was published on September 8, 2025, indicating ongoing investment opportunities in the medical equipment sector in Fujian Province [2] - Xiamen Aide Biological Medicine Technology Co., Ltd. has a significant presence in the market, having participated in 678 bidding projects and invested in 7 companies [1]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown resilience, outperforming the overall market with a 1.40% increase, while the total A-share market declined by 1.17% [1][32]. - ANGPTL3 has gained significant interest from multinational pharmaceutical companies (MNCs) due to its unique mechanism of action, which is non-LDLR dependent, making it effective in patients with LDLR deficiencies [3][30]. - The report highlights the diverse drug forms targeting ANGPTL3, with MNCs like Novartis, Lilly, Amgen, and AstraZeneca actively investing in this area, indicating a potential for multi-target and multi-drug combinations in the future [3][16]. Summary by Sections Market Performance - The overall A-share market fell by 1.17%, with the Shanghai and Shenzhen 300 index down by 0.81%. The biotechnology sector, however, rose by 1.40%, indicating strong performance relative to the broader market [1][32]. - Specific segments within the pharmaceutical sector showed varied performance, with chemical pharmaceuticals up by 3.92% and medical services up by 1.69%, while medical devices and traditional Chinese medicine saw declines [1][32]. ANGPTL3 Developments - A collaboration between Argo Biopharma and Novartis was announced, focusing on RNA drugs for cardiovascular diseases, with a total potential payment of $5.2 billion, including a $160 million upfront payment [2][11]. - ANGPTL3's mechanism allows for significant reductions in LDL-C levels in patients with HoFH, outperforming traditional treatments like PCSK9 inhibitors [3][31]. Company Earnings Forecasts and Ratings - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, have been rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion yuan [4][41]. - The report provides detailed earnings forecasts for various companies, indicating a positive outlook for the sector as a whole [4][41]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 40.75x, significantly higher than the overall A-share market's 19.80x [37][38]. - Sub-sectors such as chemical pharmaceuticals and biological products have even higher valuations, indicating strong investor interest and growth potential [37][38]. Recommended Stocks - The report recommends several companies, including Mindray Medical for its strong market position and international expansion, WuXi AppTec for its comprehensive drug development services, and Aier Eye Hospital for its leading position in the eye care sector [41][42].

Core Insights - The company has successfully launched some of its companion diagnostic products in Japan and South Korea, which have also been included in local health insurance systems [2]. Group 1 - The company confirmed that certain companion diagnostic products, such as ROS1, PCR11 gene, and FGFR2, have received approval for sale in Japan and South Korea [2].

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The IVD industry is currently facing short-term performance pressure due to medical insurance cost control and centralized procurement of IVD reagents, but a turning point is anticipated as the industry adapts to these changes [4][57]. - The global IVD market is experiencing promising growth, and the domestic IVD industry is expected to recover in the long term as it has largely completed the process of localization [5][57]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 1.40%, while the IVD sector fell by 1.97% during the week [1][10]. - The IVD sector's current Price-to-Earnings (PE) ratio is 37.38X, with a Price-to-Book (PB) ratio of 1.89X [3][29]. Financial Results - In the first half of 2025, the IVD sector reported total revenue of 18.43 billion yuan, a year-on-year decline of 15.2%, and a net profit attributable to shareholders of 2.96 billion yuan, down 27.7% year-on-year [4][51]. - The revenue and net profit decline in Q2 2025 was more pronounced compared to Q1 2025 [4][53]. Investment Recommendations - The report suggests focusing on specific growth areas within the IVD sector, particularly in immunodiagnostics, chemiluminescence, molecular diagnostics (PCR), and continuous glucose monitoring (CGM) [5][57]. - Companies such as SanNuobiology, Shengxiang Biology, and Yahui Long are highlighted as key players to watch in these segments [5][57].

Group 1 - The China (Jiangsu) Free Trade Zone has achieved a cumulative import and export value of 3.17 trillion yuan since its establishment in August 2019, with an average annual growth rate of nearly 3%, contributing to one-tenth of Jiangsu's total foreign trade import and export value [1] - The number of customs-registered enterprises in the free trade zone has increased by 122% since its inception, reaching nearly 9,400 [1] - In the first seven months of this year, the import and export value of the Jiangsu Free Trade Zone reached 336.54 billion yuan, representing a year-on-year growth of 17.15% [1] Group 2 - The "Smart Customs" platform in the Suzhou area has been launched to enhance customs declaration efficiency, serving 565 enterprises and resolving over 2,000 issues since its inception on April 25 [2] - The platform offers features such as one-click customs policy queries, system-assisted declarations, and real-time interactions between customs and enterprises, significantly reducing declaration errors [2] - The "Smart Customs" platform is available for free on the Suzhou Industrial Park's "One Network for All" website, providing various functionalities including online issuance of enterprise credit certificates [2] Group 3 - The Lianyungang area has implemented innovative regulatory models to facilitate cross-border logistics, with a China-Europe freight train departing for Kazakhstan, marking a significant trade connection [3] - The Lianyungang logistics cooperation base has utilized its geographical advantages to adopt a "one box to the end" model for the transit of Kazakh wheat, injecting new momentum into regional supply chain stability [3] - The "bonded + export" mixed container model has been introduced, saving clients approximately 73% in logistics costs, and has received positive feedback from enterprises [3]